MedTrace Logo

Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma

NCT01179256 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2010-08-11

No results posted yet for this study

Summary

Curcumin has antioxidant properties and in animal models has numerous molecular targets, many of which are intracellular, such as transcription factors AP-1 and NF. As such, it inhibits the secretion of both pro-inflammatory (TNF-, IL-6) and anti-inflammatory (IL-10) cytokines, possibly by inhibiting transcription factors such as nuclear factor-B (NF-B) and activator protein-1 (AP-1) (Wong et al).

Conditions

  • Atopic Asthma

Interventions

DIETARY_SUPPLEMENT

CURCUMIN

oral supplementation of curcumin 2000mg

OTHER

no intervention other than stopping study

no intervention other than stopping study

Sponsors & Collaborators

  • University of South Florida

    lead OTHER

Principal Investigators

  • RICHARD LOCKEY, MD · University of South Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2009-12-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01179256 on ClinicalTrials.gov